Chugai's Edirol Tablet approved in Japan as osteoporosis therapy

16 August 2022
chugai_kamakura_large

Japanese pharma major Chugai Pharmaceutical (TYO: 4519) has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for the osteoporosis treatment Edirol (eldecalcitol) Tablet (0.5µg/0.75µg).

Edirol is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research. The drug was launched in 2011 in a soft capsule formulation as Edirol Capsule, and has been used as a base drug for the treatment of osteoporosis. Due to the characteristics of the formulation, Edirol Capsule rolls easily and is hard to grasp with fingers. In addition, patients using Edirol often take other drugs, too. Considering these points, Chugai developed an alternative tablet formulation for Edirol that is easier to handle and identify. The regulatory approval for Edirol Tablet is based on the results of a bioequivalence study comparing the soft capsule and the tablet in 49 healthy adult volunteers.

To be marketed by Towa Pharma

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical